Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1350607 | 0.87 | ALDH1A1 (0.53) | ALDH1A1HPGDCYP1A2MAPTPOLB | |
| SCHEMBL8574359 | 0.83 | ALDH1A1 (0.52) | ALDH1A1HPGDMAPTSLC6A3HTT | |
| SCHEMBL156978 | 0.82 | ALDH1A1 (0.46) | ALDH1A1HPGDCYP1A2MAPTKMT2A | |
| SCHEMBL305871 | 0.82 | SLC6A3 (0.48) | ALDH1A1POLBKMT2AMEN1TDP1 | |
| SCHEMBL29696047 | 0.82 | ALDH1A1 (0.46) | ALDH1A1HPGDCYP1A2MAPTKMT2A | |
| SCHEMBL25298572 | 0.81 | ALDH1A1 (0.45) | ALDH1A1HPGDPOLBKMT2AMEN1 | |
| SCHEMBL10909 | 0.81 | ALDH1A1 (0.45) | ALDH1A1HPGDCYP1A2MAPTPOLB | |
| SCHEMBL154689 | 0.81 | ALDH1A1 (0.45) | ALDH1A1HPGDCYP1A2MAPTPOLB | |
| SCHEMBL307646 | 0.81 | ALDH1A1 (0.45) | ALDH1A1POLBKMT2AMEN1SLC6A3 | |
| SCHEMBL28132 | 0.81 | KDM4E (0.54) | ALDH1A1HPGDCYP1A2MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118754861-A | Substituted alkynylene compounds as anticancer agents | 奥里吉恩肿瘤学有限公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-111902403-B | Substituted alkynylene compounds as anticancer agents | 奥里吉恩发现科技有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-20230210847-A1 | Substituted Alkynylene Compounds As Anticancer Agents | AURIGENE ONCOLOGY LTD (IN) | 2023-07-06 | — | — | US | disclosed |
| US-11633394-B2 | Substituted alkynylene compounds as anticancer agents | AURIGENE ONCOLOGY LIMITED (IN) | 2023-04-25 | — | — | US | disclosed |
| US-20210379055-A1 | Substituted Alkynylene Compounds As Anticancer Agents | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-12-09 | — | — | US | disclosed |
| EP-3251679-B1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-12-16 | — | — | EP | disclosed |
| EP-3740473-A1 | SUBSTITUTED ALKYNYLENE COMPOUNDS AS ANTICANCER AGENTS | Aurigene Discovery Technologies Limited (IN) | 2020-11-25 | — | — | EP | disclosed |
| CN-111902403-A | Substituted alkynylene compounds as anticancer agents | 奥里吉恩发现科技有限公司 | 2020-11-06 | — | — | CN | disclosed |
| EP-2896397-B2 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-10-07 | — | — | EP | disclosed |
| EP-1651658-B2 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-08-12 | — | — | EP | disclosed |
| US-20110098469-A1 | 1-THIO-D-GLUCITOL DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
| US-7910619-B2 | e.g. 2,3,4,6-tetra-O-benzyl-5-thio-D-glucono-1,5-lactone3,4-Dihydro-2H-pyran; inhibit the activity of sodium-dependent glucose cotransporter 2 (SGLT2) concerned with glucose reabsorption in the kidney; antidiabetic agent; diabetes-related disease, or diabetic complication | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| EP-2046346-A1 | NOVEL SGLT INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20080132563-A1 | 1-Thio-D-Glucitol Derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| US-20080027014-A1 | Novel SGLT inhibitors | TANABE SEIYAKU CO., LTD. | 2008-01-31 | — | — | US | disclosed |
| WO-2008013321-A1 | NOVEL SGLT INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-01-31 | — | — | WO | disclosed |
| EP-1845095-A1 | 1-THIO-D-GLUCITOL DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-10-17 | — | — | EP | disclosed |
| EP-1651658-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | TANABE SEIYAKU CO., LTD. (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-20050233988-A1 | Novel compounds | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-20 | — | — | US | disclosed |
| WO-2005012326-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | TANABE SEIYAKU CO., LTD. (JP) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050233988-A1 | Novel compounds | CYP1B1, CYP4B1, CYP2B6 | ALDH1A1 831/4885HPGD 391/4885CYP1A2 21/4885 |
| US-20230210847-A1 | Substituted Alkynylene Compounds As Anticancer Agents | MCL1, ROS1, MKI67 | ALDH1A1 25/4885HPGD 1440/4885CYP1A2 1114/4885 |
| US-20210379055-A1 | Substituted Alkynylene Compounds As Anticancer Agents | MCL1, ROS1, MKI67 | ALDH1A1 25/4885HPGD 1440/4885CYP1A2 1114/4885 |
| US-20110098469-A1 | 1-THIO-D-GLUCITOL DERIVATIVES | SLC5A1, SLC5A2, SLC5A11 | ALDH1A1 251/4885HPGD 774/4885CYP1A2 1227/4885 |
| US-20080027014-A1 | Novel SGLT inhibitors | SLC5A1, SLC5A2, SLC10A1 | ALDH1A1 670/4885HPGD 2123/4885CYP1A2 2114/4885 |
| US-11633394-B2 | Substituted alkynylene compounds as anticancer agents | MCL1, ROS1, MKI67 | ALDH1A1 25/4885HPGD 1440/4885CYP1A2 1114/4885 |
| US-20080132563-A1 | 1-Thio-D-Glucitol Derivatives | SLC5A1, SLC5A2, SLC5A11 | ALDH1A1 251/4885HPGD 774/4885CYP1A2 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.